Resistance to Molecular Therapies for Hepatocellular Carcinoma

  • Augusto Villanueva

Part of the Resistance to Targeted Anti-Cancer Therapeutics book series (RTACT, volume 13)

Table of contents

  1. Front Matter
    Pages i-xiii
  2. Amanda J. Craig, Ismail Labgaa, Carlos Villacorta-Martin, Massih Ningarhari, Augusto Villanueva
    Pages 1-24
  3. Darko Castven, Carolin Czauderna, Jens U. Marquardt
    Pages 65-91
  4. Maria Reig, Álvaro Díaz-Gonzalez, Andrea Ribeiro, Anna Darnell
    Pages 117-131
  5. Back Matter
    Pages 143-147

About this book


This volume evaluates the clinical patterns of resistance to sorafenib, the impact of trial design in the second-line setting and the current gold standard to define radiological resistance; describes the molecular mechanisms responsible for treatment resistance in HCC patients, including components of the immune system and tumor microenvironment; determines the role of the cancer stem cell phenotype in resistance; reviews the experimental models to study resistance; and addresses new approaches to overcome resistance to sorafenib, using successful examples from other malignancies.


Cancer stem cell phenotype Carcinoma Hapatocellular Carcinoma Liver cancer Sorafenib

Editors and affiliations

  • Augusto Villanueva
    • 1
  1. 1.Division of Liver Diseases, Tisch Cancer InstituteIcahn School of Medicine at Mount Sinai, Graduate School of Biomedical SciencesNew YorkUSA

Bibliographic information

Industry Sectors
Health & Hospitals
Oncology & Hematology
Consumer Packaged Goods